Evidence map›Paper›PMID 37577493›Full record

ArticlemedRxiv : the preprint server for health sciences2023

SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency.

Yijia Li, Manish C Choudhary, James Regan, Julie Boucau, Anusha Nathan, Tessa Speidel, May Yee Liew, Gregory E Edelstein, Yumeko Kawano, Rockib Uddin and 23 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 5 institutions in 1 country.

Yijia LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Manish C ChoudharyDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
James ReganDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Anusha NathanRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Tessa SpeidelCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
May Yee LiewDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gregory E EdelsteinDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yumeko KawanoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rockib UddinDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rinki DeoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Caitlin MarinoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Matthew A GetzRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Zahra ReynoldDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mamadou BarryDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rebecca F GilbertDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dessie TienDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Shruti SagarDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tammy D VyasDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
James P FlynnDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sarah P HammondDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Lewis A NovackDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Bina ChoiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Manuela CernadasDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Zachary S WallaceDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jeffrey A SparksDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jatin M VyasDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Gaurav D GaihaDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mark J SiednerDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Amy K BarczakDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jacob E LemieuxDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USBroad Institute · USRagon Institute of MGH, MIT and Harvard · USBeth Israel Deaconess Medical Center · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI PARK, DANIEL JOHN · 2014 to 2024
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV CureDP1DA058476 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$4.7M
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA RepliconsR01AI176533 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$3.5M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7M
NIAID NIH HHS DP2 AI154421NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI176533NIAID NIH HHS U19 AI110818NIAMS NIH HHS R01 AR080659NIDA NIH HHS DP1 DA058476
6 · The paper itself

Abstract

Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent COVID-19 remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median time to nasal viral RNA and culture clearance in the severe hematologic malignancy/transplant group (S-HT) were 72 and 40 days, respectively, which were significantly longer than clearance rates in the severe autoimmune/B-cell deficient (S-A), non-severe, and non-immunocompromised groups (P<0.001). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and a higher risk of developing antiviral treatment resistance. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral, while only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection.

Identifiers

PMID37577493
PMCPMC10418302
OpenAlexW4385497490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.